LENZ Therapeutics Inc.
LENZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$243.94M
Close$
$1.08
84.6% downside
Current Fair Value
84.6% downsideOvervalued by 84.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $243.94 Million |
|---|---|
| Enterprise Value | $219.40 Million |
| Dividend Yield | $7.21 (-) |
| Earnings per Share | $-2.85 |
| Beta | 1.67 |
| Outstanding Shares | 31,352,702 |
Return
| Return on Equity | -44.22% |
|---|---|
| Return on Assets | -39.99% |
| Return on Invested Capital | -48.01% |
Valuation & Multiples
| P/E Ratio | -2.24 |
|---|---|
| PEG | -1.22 |
| Price to Sales | - |
| Price to Book Ratio | 1.0 |
| Enterprise Value to Revenue | 10.45 |
| Enterprise Value to EBIT | -1.85 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 11, 2026
EPS Estimate
$-1.10
Average shareholder expectationRevenue Estimate
$1.76 M
Average shareholder expectationNext Earnings Call
Expected Date
July 29, 2026
EPS Estimate
$-1.07
Average shareholder expectationRevenue Estimate
$2.49 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 2.3129▼ 148.62% |
|---|---|
| Total Calls | 104,200▲ 23.90% |
| Total Puts | 241,000▼ 24.57% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 106.66%▼ 16.23% |
|---|---|
| Total Invested | $303.30M▼ 45.99% |
| Investors Holding | 150▼ 18.00% |
ESG Score
No data
About LENZ Therapeutics Inc.
119 employeesgraphite bio is a next-generation gene editing company focused on the development of first-in-class therapies for patients suffering from life-threatening genetic diseases. the company’s platform harnesses the natural cellular process of...